VBCG
GILD icon

Valley Brook Capital Group’s Gilead Sciences GILD Stock Holding History

Valley Brook Capital Group’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-50
Closed -$2K – 474
2020
Q4 		$2K Buy
+50
New +$3.02K ﹤0.01% 378

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Valley Brook Capital Group's GILD Position: Q1 2021 in Review

Valley Brook Capital Group sold out of Gilead Sciences (GILD) in Q1 2021, closing a stake of 50 shares — an estimated $2K sold.

Valley Brook Capital Group first reported a position in GILD in Q4 2020 and held it in 1 quarter. The position peaked at $2K in Q4 2020. 1,567 funds tracked by Wall St. Rank hold GILD as of Q1 2021.

  • Valley Brook Capital Group reported no remaining Gilead Sciences position as of Q1 2021 after selling out during the quarter.
  • Valley Brook Capital Group sold 50 Gilead Sciences shares in Q1 2021, an estimated $2K.
  • Valley Brook Capital Group first reported a position in Gilead Sciences in Q4 2020 and held it in 1 quarter.
  • Valley Brook Capital Group's Gilead Sciences position peaked at $2K in Q4 2020.
  • 1,567 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2021.

Based on Valley Brook Capital Group's 13F filing for Q1 2021, filed 6 May 2021.